Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1504079

Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report

Provisionally accepted
Luping Zhao Luping Zhao *Victor Cheng Victor Cheng Piaopiao Li Piaopiao Li
  • Dongyang People’s Hospital, Dongyang, China

The final, formatted version of the article will be published soon.

    Background: This study reports a case of severe cutaneous toxicity in a patient with metastatic gastric cancer induced by disitamab vedotin, emphasizing the need for careful monitoring and management in such treatments. Case presentation: A 71-year-old female was admitted to hospital complaining of serious rashes following the first cycle of disitamab vedotin regimen for metastatic gastric cancer. The doctor diagnosedtoxic epidermal necrolysis (TEN) induced by the drug. The patient received high-dose methylprednisolone due to the side effects.This resulted in a gradual improvement of symptoms. Conclusion: During the use of disitamab vedotin, patients need to be monitored for severe skin toxicity.

    Keywords: Disitamab vedotin, case report, severe cutaneous drug toxicity, adverse effects, Metastatic gastric cancer

    Received: 30 Sep 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Zhao, Cheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Luping Zhao, Dongyang People’s Hospital, Dongyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.